NCT04619069View on ClinicalTrials.gov

Intermittent Androgen Deprivation Therapy With or Without Stereotactic Body Radiotherapy for Molecularly Identified Hormone Sensitive Oligometastatic Prostate Cancer

PHASE1/PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

60

Participants

Timeline

Start Date

October 27, 2020

Primary Completion Date

December 31, 2025

Study Completion Date

October 31, 2027

Conditions
Prostate Cancer
Interventions
RADIATION

SBRT

SBRT to all sites of metastatic disease as seen on PSMA PET scan

DRUG

Hormone therapy

Intermittent Hormone Therapy per physician discretion (Min. 8 months)

Trial Locations (1)

M4N3M5

Odette Cancer Centre, Toronto

All Listed Sponsors
lead

Sunnybrook Health Sciences Centre

OTHER